
Opinion|Videos|July 18, 2024
Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis
Author(s)Shawn Kwatra, MD
Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
- Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
- Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
3
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
4
IL-13 Inhibitor Response Can Guide Patch Testing Decisions in Eczematous Dermatitis
5
























































































